To target tumor growth, our research group previously generated an immunoglobulin G (IgG) monoclonal antibody (mAb) directed against the fibroblast growth factor 2 (FGF2)6, based on the conventional hybridoma technology7. Here, FGF2 is linked to neoplasm.